The Canadian health-tech sector faces regulatory challenges amidst rapid innovations in artificial intelligence (AI), digital health, biotechnology, and medical devices. This paper explores the regulatory landscape based on stakeholder interviews and proposes a framework that balances patient safety with innovation. Key elements include open data access, long-term government funding, monitoring of anti-competitive behavior, and alignment with international standards.